Novapeutics LLC (Novapeutics) is a biopharmaceutical company that develops oral curative therapeutics to reverse the course of diabetes by regenerating insulin-producing beta cells. The company develops menin inhibitor, a small molecule that stimulates the insulin-producing beta-cells in the pancreas to regenerate. Its novel inhibitor helps increase functional pancreatic beta-cells and reduces stress in beta-cells to optimize the endogenous insulin output in diabetes patients. The company’s drug screening platform identifies compounds such as CDH1 and CDH2, which inhibit the menin and mixed lineage leukaemia-1 interaction. Novapeutics is headquartered in Philadelphia, Pennsylvania, US.